| |
Newsroom /
Industry
/
Industry
/
Upstream Processing in Biopharmaceuticals
Upstream Processing in Biopharmaceuticals
Strong Growth is expected in the Overall Upstream Process market
London,
London,
United Kingdom
(prbd.net)
02/03/2011
Upstream process is vital in the manufacturing of biopharmaceuticals to have control over growth conditions and nutrients which eventually reflects in an increased overall yield. GBI Research analysis shows that the total upstream market was calculated at $5.4 billion in 2009. The market is expected to grow at a CAGR of 11% for the period 2009-2016, and is expected to reach $11.7 billion by 2016. Advancement in cell culture technologies, innovation in the transgenic production system and the rising demand for biologics is expected to drive the upstream process market.
For Sample Pages, please click or add the below link to your browser:
http://gbiresearch.com/RequestSamplePages.aspx?ID=Upstream-Processing-in-Biopharmaceuticals-Increasing-use-of-Low-Cost-Disposable-Bioreactors-to-Drive-the-Upstream-Bioprocessing-Market&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
Outsourcing to Contract Manufacturing Organization (CMOs) is one of the most significant trends in the healthcare industry, especially in the biopharmaceuticals market. CMOs will be used for most of the processes in the healthcare industry several players from emerging countries are entering the market. Companies from the US and Europe are opening up operations in emerging countries such as India, Korea, China and Singapore. Outsourcing to the CMO is a good option for the big biotechnology companies that want to focus on core competency. Similarly companies lacking the manufacturing infrastructure and technical expertise are outsourcing to the CMO.
GBI Research analysis shows that the CMO market for upstream processing was $1.2 billion in 2009 and is expected to grow at a CAGR of 14% to reach at a value of $2.8bn in 2016. The major factor driving the CMO market is the increase in the trend of outsourcing of biopharmaceutical manufacturing to the CMO.
Cell culture and reagent is a consolidated market. More than 85%-90% of production of cell culture media, sera, and reagent used in the upstream processing are dominated by a few companies such as Life Technologies and Sigma Aldrich. Increasing interest of emerging countries in the production of biopharmaceutical drugs; patent expiry of some major dugs; and regulatory acceptances to the biosimilars is expected to drive the market in future.
GBI Research's report, “Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market”, provides the key to market data on overall upstream process, Contract Manufacturing Organization (CMO) market for upstream processing, and the cell culture and reagent market. Market. The report also analyzes the strengths, weaknesses, opportunities, and threats for the key players in the CMO and cell culture and regent market. The report also discusses the key market drivers and restraints for the upstream processing, outsourcing to CMO and cell culture and reagent market. The report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts to provide a comprehensive view of the upstream processing in biopharmaceuticals.
For further details, please click or add the below link to your browser:
http://gbiresearch.com/Report.aspx?ID=Upstream-Processing-in-Biopharmaceuticals-Increasing-use-of-Low-Cost-Disposable-Bioreactors-to-Drive-the-Upstream-Bioprocessing-Market&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare
Visit our report store: http://www.gbiresearch.com
For more details contact:
pressreleases@gbiresearch.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GBI Research is a global market intelligence services company providing information research and analysis products and services.
|